

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

			•		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/648,593	08/26/2003	Fei Huang	D0273 NP	5265	
	7590 04/26/2007	EXAMINER			
LOUIS J. WILLE BRISTOL-MYERS SQUIBB COMPANY			SWOPE, SHERIDAN		
PATENT DEPA P O BOX 4000		ART UNIT	PAPER NUMBER		
PRINCETON,		1652			
	•		MAIL DATE	DELIVERY MODE	
			04/26/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/648,593	HUANG ET AL.		
Examiner	Art Unit		
Sheridan L. Swope	1652		

	٠.	Sheridan L. Swope	1652				
The MAILING DATE	of this communication appe	ars on the cover sheet with	the correspondence add	ress			
THE REPLY FILED 18 April 2007	FAILS TO PLACE THIS APP	LICATION IN CONDITION FO	R ALLOWANCE.				
The reply was filed after a fi this application, applicant m places the application in co	nal rejection, but prior to or on nust timely file one of the follow ndition for allowance; (2) a No		e of Appeal. To avoid aba t, affidavit, or other evider) in compliance with 37 C	nce, which FR 41.31; or (3)			
a) The period for reply expireb) The period for reply expire		Advisory Action, or (2) the date set					
Examiner Note: If box 1 is		ater than SIX MONTHS from the m (b). ONLY CHECK BOX (b) WHEN 06 07(f)	-				
Extensions of time may be obtained unave been filed is the date for purpost under 37 CFR 1.17(a) is calculated from the first forth in (b) above, if checked. Any may reduce any earned patent term a NOTICE OF APPEAL	under 37 CFR 1.136(a). The date es of determining the period of ex om: (1) the expiration date of the y reply received by the Office later	on which the petition under 37 CF tension and the corresponding am shortened statutory period for reply r than three months after the mailir	ount of the fee. The appropri originally set in the final Offi	iate extension fee ce action; or (2) as			
	(37 CFR 41.37(a)), or a	in compliance with 37 CFR 41. Iny extension thereof (37 CFR y must be filed within the time	41.37(e)), to avoid dismis	sal of the			
B. The proposed amendment	(s) filed after a final rejection,	but prior to the date of filing a	brief, will not be entered b	ecause			
		nsideration and/or search (see					
· · · = ·	of new matter (see NOTE belo	• •		•			
(c) ∐ They are not deemed appeal; and/or	to place the application in be	tter form for appeal by materia	lly reducing or simplifying	the issues for			
(d) 🔲 They present additior	al claims without canceling a	corresponding number of final	y rejected claims.				
. NOTE: <u>See Continu</u>	lation Sheet. (See 37 CFR 1.1	16 and 41.33(a)).					
 The amendments are not in 	n compliance with 37 CFR 1.1	21. See attached Notice of No	n-Compliant Amendment	(PTOL-324).			
5. 🔲 Applicant's reply has over	come the following rejection(s)):					
 Newly proposed or amend non-allowable claim(s). 	ed claim(s) would be a	llowable if submitted in a sepa	rate, timely filed amendme	ent canceling the			
 For purposes of appeal, the how the new or amended c The status of the claim(s) is 	laims would be rejected is pro] will be entered and an e	explanation of			
Claim(s) allowed:		•	4				
Claim(s) objected to: Claim(s) rejected: <u>41</u> .							
Claim(s) withdrawn from co							
AFFIDAVIT OR OTHER EVIDEN							
 The affidavit or other evider because applicant failed to was not earlier presented. 	provide a showing of good an	It before or on the date of filing d sufficient reasons why the at					
	vit or other evidence failed to o	a Notice of Appeal, but prior to overcome <u>all</u> rejections under a y and was not earlier presente	appeal and/or appellant fai	ils to provide a			
10. ☐ The affidavit or other evide	ence is entered. An explanatio	•		•			
REQUEST FOR RECONSIDERA		·					
11. The request for reconside				nce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)							
	•	•					
				•			

Continuation of 3. NOTE: The pending claim, Claim 41, has been amended to recited a method using a compound that is an inhibitor of all of Src, Fgr, Fyn, Yes, Blk, Hck, Lck, Lyn, BCR-ABL, PDGFR, c-Kit, and EphA2. Examination of said claim requires additional searching of the prior art as well as analysis under 35 USC 101, 112, 102, and 103.

SHERIDAN SWOPE, PH.D PRIMARY EXAMINER